Prescription drug · ANDA
Acitretin NDC 0378-7020
Acitretin 10 mg/1 · Capsule · Oral · Mylan Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0378-7020-93 | 00378702093 | 30 CAPSULE in 1 BOTTLE, PLASTIC (0378-7020-93)Marketed from Mar 10, 2016 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Acitretin
- Generic name (nonproprietary)
- acitretin
- Active ingredients
- Acitretin — 10 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Mylan Pharmaceuticals Inc.NDC labeler code 0378
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202148
- Marketing start
- Listing expires
- Other FDA classes
- Retinoids (Chemical structure)
- Identifiers
- Product ID 0378-7020_4e629ef9-879a-443d-9397-c47962855dd8SPL ID 4e629ef9-879a-443d-9397-c47962855dd8SPL set ID 2150bb0f-551b-4059-a97b-187d3ab22519RxCUI 199689, 199690UNII LCH760E9T7
- Pharmacologic class
- Retinoid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400378702093followed by a unit qualifier and the quantityPackage 00378-7020-93. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, acitretin capsules should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, acitretin capsules should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS - Acitretin capsules can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated…
Excerpt only. Read the full label for complete information.
About NDC 0378-7020
- What is NDC 0378-7020?
- 0378-7020 is the product NDC for Acitretin, Acitretin 10 mg/1 capsule, listed with the FDA by Mylan Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Acitretin.
- What is the active ingredient?
- Acitretin.
- Who is the labeler?
- Mylan Pharmaceuticals Inc., NDC labeler code 0378. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Acitretin?
- 21 other product NDCs are listed under this name. See all Acitretin NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Acitretin products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-741 | 46708-0741-30 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-742 | 46708-0742-30 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Alembic Pharmaceuticals Limited | 46708-743 | 46708-0743-30 |
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-741 | 62332-0741-30 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-742 | 62332-0742-30 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Alembic Pharmaceuticals Inc. | 62332-743 | 62332-0743-30 |
| Acitretin | Acitretin 10 mg/1 | CapsuleOral | AvKARE | 42291-086 | 42291-0086-30 |
| Acitretin | Acitretin 17.5 mg/1 | CapsuleOral | AvKARE | 42291-087 | 42291-0087-30 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | AvKARE | 42291-088 | 42291-0088-30 |
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Mylan Pharmaceuticals Inc. | 0378-7023 | 00378-7023-93 |
Other NDCs under ANDA 202148
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Acitretin | Acitretin 25 mg/1 | CapsuleOral | Mylan Pharmaceuticals Inc. | 0378-7023 |